- Home
- Â /Â Horizon Therapeutics
Horizon Therapeutics
Revenue
$3.6 B
FY, 2022
Horizon Therapeutics Summary
Company Summary
- Overview
- Horizon Therapeutics is a biopharmaceutical company focused on researching, developing, and commercializing medicines. It offers products to treat rare, autoimmune, and inflammatory diseases. Its products include TEPEZZA, KRYSTEXXA, RAVICTI, PROCYSBI, UPLIZNA, ACTIMMUNE, etc. The company also provides patient advocacy, disease education, and patient support programs.
- Type
- Subsidiary
- Status
- Active
- Founded
- 2008
- HQ
- Dublin, IE | view all locations
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Irina Konstantinovsky, Executive Vice President, Chief Human Resources
Jane Gonnerman, Senior Vice President, Corporate Develoment and Chief of Staff, Office of the CEO
Jessica Hartung, Regional Medical Director
Operating MetricsView all
Pre-Clinical Phase Products
4
33.3%
Sep, 2021
Products
11
10.0%
FY, 2020
Phase 3b/4 Trials Products
3
50.0%
FY, 2019
Horizon Therapeutics Financials
Summary Financials
- Revenue (Q2, 2023)
- $945.0M
- Gross profit (Q2, 2023)
- $725.0M
- Net income (Q2, 2023)
- $127.1M
- Cash (Q2, 2023)
- $2.5B
- EBIT (Q2, 2023)
- $142.8M